Enigma Announces Successful Completion of EU Framework 7 "RANGER" Project

OXFORD, England, July 18, 2011 -

In October 2007, Enigma Diagnostics (Porton Down, UK & San
Diego, USA) announced the award of a euro 3 Million grant by the
European Commission Framework 7 programme. This EU Commission award
was won in a competitive process and the grant was to support
development of a rapid, fully automated molecular diagnostic system
for Seasonal Influenza (circulating strains of Influenza types A
& B) to be based on Enigma’s concept ML (mini-laboratory)
instrument system. The RANGER project started on 1st of July 2008
with a consortium of members. This was led by Enigma Diagnostics
and included the UK Health Protection Agency (HPA) with
responsibility for assay development, Sagentia (Harston, Cambridge,
UK) supporting development of the Enigma® ML prototype system and
Queen Sirikit National Institute of Child Health collecting samples
for clinical trials. PERA administered the project on behalf of the
consortium.

The concluding meeting of the RANGER consortium was held at
Enigma’s Oxford site on 30th June 2011 at which Enigma demonstrated
the use of the Enigma® ML system from sample to result in less than
60 minutes, using a swab and running a Seasonal Influenza,
real-time PCR assay.  

John McKinley, Chairman of Enigma Diagnostics, said, “Enigma and
all of the RANGER consortium recognise the valuable contribution of
the EU Commission in supporting the successful development of the
Enigma® ML system. This has progressed from initial design concept
to pre-clinical assessment of the Seasonal Influenza test at the
HPA Porton Down laboratories earlier this year. The Enigma® ML
system will now move to the commercialization stage during
2012.”

The Enigma® ML system will be showcased at AACC (American
Association for Clinical Chemistry) at stand116 from 26th to 28th
July 2011.  

The research leading to these results
has received funding from the European Community’s Seventh
Framework Programme (FP7/2007-2013) under grant agreement no.
201569.

About Enigma Diagnostics Limited

Enigma Diagnostics Limited specialises in developing next
generation rapid molecular diagnostic instrument platforms for
decentralized and point-of-care settings. Enigma’s innovative and
proprietary technologies combine the speed and sensitivity of
real-time PCR (polymerase chain reaction) with the simplicity
needed for decentralized and point-of-care testing providing
results from a raw sample in less than 60 minutes. The Company is
targeting a number of multi-billion pound markets, core among which
are the Clinical and high-value Applied Markets. Enigma’s
commercialization strategy is to maximize revenues from a
continuous flow of market leading rapid diagnostic point-of care
instrument and assay platforms, based on unique technologies and
underpinned by its broad Intellectual Property portfolio. Enigma
will partner with market leaders where global penetration of
markets is required and where appropriate, will engage regional
partners and build in-house sales and marketing capability to
direct distribution of its products.

For more information visit href="www.enigmadiagnostics.com/">www.enigmadiagnostics.com

Press Contact:
Tatjana Quinn
Telephone: +44-(0)-1235-854076
href="mailto:tatjana.quinn@enigmadiagnostics.com">tatjana.quinn@enigmadiagnostics.com

.